0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Incretin-Based Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-16A7421
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Incretin Based Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Incretin-Based Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-16A7421
Report
September 2024
Pages:96
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Incretin-Based Drugs - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Incretin-Based Drugs - Market

Incretin-Based Drugs - Market

The global market for Incretin-Based Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Incretin-Based Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Incretin-Based Drugs by region & country, by Type, and by Application.
The Incretin-Based Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Incretin-Based Drugs.
Market Segmentation

Scope of Incretin-Based Drugs - Market Report

Report Metric Details
Report Name Incretin-Based Drugs - Market
CAGR 5%
Segment by Type:
  • Glucagon-like peptide-1 receptor (GLP-1) agonists
  • Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company, Sanofi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Incretin-Based Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Incretin-Based Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Incretin-Based Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Incretin-Based Drugs - Market report?

Ans: The main players in the Incretin-Based Drugs - Market are GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company, Sanofi

What are the Application segmentation covered in the Incretin-Based Drugs - Market report?

Ans: The Applications covered in the Incretin-Based Drugs - Market report are Oral Drugs, Injectable Drugs

What are the Type segmentation covered in the Incretin-Based Drugs - Market report?

Ans: The Types covered in the Incretin-Based Drugs - Market report are Glucagon-like peptide-1 receptor (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors

Recommended Reports

Diabetes & Weight Drugs

Cardio & Cholesterol

Drug APIs & Generics

1 Market Overview
1.1 Incretin-Based Drugs Product Introduction
1.2 Global Incretin-Based Drugs Market Size Forecast
1.2.1 Global Incretin-Based Drugs Sales Value (2019-2030)
1.2.2 Global Incretin-Based Drugs Sales Volume (2019-2030)
1.2.3 Global Incretin-Based Drugs Sales Price (2019-2030)
1.3 Incretin-Based Drugs Market Trends & Drivers
1.3.1 Incretin-Based Drugs Industry Trends
1.3.2 Incretin-Based Drugs Market Drivers & Opportunity
1.3.3 Incretin-Based Drugs Market Challenges
1.3.4 Incretin-Based Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Incretin-Based Drugs Players Revenue Ranking (2023)
2.2 Global Incretin-Based Drugs Revenue by Company (2019-2024)
2.3 Global Incretin-Based Drugs Players Sales Volume Ranking (2023)
2.4 Global Incretin-Based Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Incretin-Based Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Incretin-Based Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Incretin-Based Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Incretin-Based Drugs
2.9 Incretin-Based Drugs Market Competitive Analysis
2.9.1 Incretin-Based Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Incretin-Based Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Incretin-Based Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Glucagon-like peptide-1 receptor (GLP-1) agonists
3.1.2 Dipeptidyl Peptidase-4 (DPP-4) inhibitors
3.2 Global Incretin-Based Drugs Sales Value by Type
3.2.1 Global Incretin-Based Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Incretin-Based Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Incretin-Based Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Incretin-Based Drugs Sales Volume by Type
3.3.1 Global Incretin-Based Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Incretin-Based Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Incretin-Based Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Incretin-Based Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oral Drugs
4.1.2 Injectable Drugs
4.2 Global Incretin-Based Drugs Sales Value by Application
4.2.1 Global Incretin-Based Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Incretin-Based Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Incretin-Based Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Incretin-Based Drugs Sales Volume by Application
4.3.1 Global Incretin-Based Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Incretin-Based Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Incretin-Based Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Incretin-Based Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Incretin-Based Drugs Sales Value by Region
5.1.1 Global Incretin-Based Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Incretin-Based Drugs Sales Value by Region (2019-2024)
5.1.3 Global Incretin-Based Drugs Sales Value by Region (2025-2030)
5.1.4 Global Incretin-Based Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Incretin-Based Drugs Sales Volume by Region
5.2.1 Global Incretin-Based Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Incretin-Based Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Incretin-Based Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Incretin-Based Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Incretin-Based Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Incretin-Based Drugs Sales Value, 2019-2030
5.4.2 North America Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Incretin-Based Drugs Sales Value, 2019-2030
5.5.2 Europe Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Incretin-Based Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Incretin-Based Drugs Sales Value, 2019-2030
5.7.2 South America Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Incretin-Based Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Incretin-Based Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Incretin-Based Drugs Sales Value
6.2.1 Key Countries/Regions Incretin-Based Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Incretin-Based Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Incretin-Based Drugs Sales Value, 2019-2030
6.3.2 United States Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Incretin-Based Drugs Sales Value, 2019-2030
6.4.2 Europe Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Incretin-Based Drugs Sales Value, 2019-2030
6.5.2 China Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Incretin-Based Drugs Sales Value, 2019-2030
6.6.2 Japan Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Incretin-Based Drugs Sales Value, 2019-2030
6.7.2 South Korea Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Incretin-Based Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Incretin-Based Drugs Sales Value, 2019-2030
6.9.2 India Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Incretin-Based Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Information
7.1.2 GlaxoSmithKline Introduction and Business Overview
7.1.3 GlaxoSmithKline Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 GlaxoSmithKline Incretin-Based Drugs Product Offerings
7.1.5 GlaxoSmithKline Recent Development
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Information
7.2.2 Johnson & Johnson Introduction and Business Overview
7.2.3 Johnson & Johnson Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Johnson & Johnson Incretin-Based Drugs Product Offerings
7.2.5 Johnson & Johnson Recent Development
7.3 Merck & Co
7.3.1 Merck & Co Company Information
7.3.2 Merck & Co Introduction and Business Overview
7.3.3 Merck & Co Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Merck & Co Incretin-Based Drugs Product Offerings
7.3.5 Merck & Co Recent Development
7.4 AstraZeneca
7.4.1 AstraZeneca Company Information
7.4.2 AstraZeneca Introduction and Business Overview
7.4.3 AstraZeneca Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 AstraZeneca Incretin-Based Drugs Product Offerings
7.4.5 AstraZeneca Recent Development
7.5 Novartis
7.5.1 Novartis Company Information
7.5.2 Novartis Introduction and Business Overview
7.5.3 Novartis Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Novartis Incretin-Based Drugs Product Offerings
7.5.5 Novartis Recent Development
7.6 Eli Lilly and Company
7.6.1 Eli Lilly and Company Company Information
7.6.2 Eli Lilly and Company Introduction and Business Overview
7.6.3 Eli Lilly and Company Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Eli Lilly and Company Incretin-Based Drugs Product Offerings
7.6.5 Eli Lilly and Company Recent Development
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Company Information
7.7.2 Boehringer Ingelheim Introduction and Business Overview
7.7.3 Boehringer Ingelheim Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Boehringer Ingelheim Incretin-Based Drugs Product Offerings
7.7.5 Boehringer Ingelheim Recent Development
7.8 Takeda Pharmaceutical Company
7.8.1 Takeda Pharmaceutical Company Company Information
7.8.2 Takeda Pharmaceutical Company Introduction and Business Overview
7.8.3 Takeda Pharmaceutical Company Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Takeda Pharmaceutical Company Incretin-Based Drugs Product Offerings
7.8.5 Takeda Pharmaceutical Company Recent Development
7.9 Sanofi
7.9.1 Sanofi Company Information
7.9.2 Sanofi Introduction and Business Overview
7.9.3 Sanofi Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Sanofi Incretin-Based Drugs Product Offerings
7.9.5 Sanofi Recent Development
8 Industry Chain Analysis
8.1 Incretin-Based Drugs Industrial Chain
8.2 Incretin-Based Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Incretin-Based Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Incretin-Based Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Incretin-Based Drugs Market Trends
    Table 2. Incretin-Based Drugs Market Drivers & Opportunity
    Table 3. Incretin-Based Drugs Market Challenges
    Table 4. Incretin-Based Drugs Market Restraints
    Table 5. Global Incretin-Based Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Incretin-Based Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global Incretin-Based Drugs Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Incretin-Based Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Incretin-Based Drugs Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers Incretin-Based Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Incretin-Based Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Incretin-Based Drugs
    Table 13. Global Incretin-Based Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Incretin-Based Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Incretin-Based Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Incretin-Based Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Incretin-Based Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Incretin-Based Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Incretin-Based Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Incretin-Based Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Incretin-Based Drugs Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Incretin-Based Drugs Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Incretin-Based Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Incretin-Based Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Incretin-Based Drugs Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global Incretin-Based Drugs Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global Incretin-Based Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Incretin-Based Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Incretin-Based Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Incretin-Based Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Incretin-Based Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Incretin-Based Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Incretin-Based Drugs Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Incretin-Based Drugs Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Incretin-Based Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Incretin-Based Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Incretin-Based Drugs Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global Incretin-Based Drugs Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global Incretin-Based Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Incretin-Based Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Incretin-Based Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Incretin-Based Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global Incretin-Based Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global Incretin-Based Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Incretin-Based Drugs Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Incretin-Based Drugs Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Incretin-Based Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Incretin-Based Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Incretin-Based Drugs Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global Incretin-Based Drugs Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions Incretin-Based Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Incretin-Based Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Incretin-Based Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Incretin-Based Drugs Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Incretin-Based Drugs Sales Volume, (2025-2030) & (K Units)
    Table 57. GlaxoSmithKline Company Information
    Table 58. GlaxoSmithKline Introduction and Business Overview
    Table 59. GlaxoSmithKline Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. GlaxoSmithKline Incretin-Based Drugs Product Offerings
    Table 61. GlaxoSmithKline Recent Development
    Table 62. Johnson & Johnson Company Information
    Table 63. Johnson & Johnson Introduction and Business Overview
    Table 64. Johnson & Johnson Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. Johnson & Johnson Incretin-Based Drugs Product Offerings
    Table 66. Johnson & Johnson Recent Development
    Table 67. Merck & Co Company Information
    Table 68. Merck & Co Introduction and Business Overview
    Table 69. Merck & Co Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. Merck & Co Incretin-Based Drugs Product Offerings
    Table 71. Merck & Co Recent Development
    Table 72. AstraZeneca Company Information
    Table 73. AstraZeneca Introduction and Business Overview
    Table 74. AstraZeneca Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. AstraZeneca Incretin-Based Drugs Product Offerings
    Table 76. AstraZeneca Recent Development
    Table 77. Novartis Company Information
    Table 78. Novartis Introduction and Business Overview
    Table 79. Novartis Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Novartis Incretin-Based Drugs Product Offerings
    Table 81. Novartis Recent Development
    Table 82. Eli Lilly and Company Company Information
    Table 83. Eli Lilly and Company Introduction and Business Overview
    Table 84. Eli Lilly and Company Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 85. Eli Lilly and Company Incretin-Based Drugs Product Offerings
    Table 86. Eli Lilly and Company Recent Development
    Table 87. Boehringer Ingelheim Company Information
    Table 88. Boehringer Ingelheim Introduction and Business Overview
    Table 89. Boehringer Ingelheim Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 90. Boehringer Ingelheim Incretin-Based Drugs Product Offerings
    Table 91. Boehringer Ingelheim Recent Development
    Table 92. Takeda Pharmaceutical Company Company Information
    Table 93. Takeda Pharmaceutical Company Introduction and Business Overview
    Table 94. Takeda Pharmaceutical Company Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 95. Takeda Pharmaceutical Company Incretin-Based Drugs Product Offerings
    Table 96. Takeda Pharmaceutical Company Recent Development
    Table 97. Sanofi Company Information
    Table 98. Sanofi Introduction and Business Overview
    Table 99. Sanofi Incretin-Based Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 100. Sanofi Incretin-Based Drugs Product Offerings
    Table 101. Sanofi Recent Development
    Table 102. Key Raw Materials Lists
    Table 103. Raw Materials Key Suppliers Lists
    Table 104. Incretin-Based Drugs Downstream Customers
    Table 105. Incretin-Based Drugs Distributors List
    Table 106. Research Programs/Design for This Report
    Table 107. Key Data Information from Secondary Sources
    Table 108. Key Data Information from Primary Sources
List of Figures
    Figure 1. Incretin-Based Drugs Product Picture
    Figure 2. Global Incretin-Based Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Incretin-Based Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Incretin-Based Drugs Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Incretin-Based Drugs Sales Price (2019-2030) & (US$/Unit)
    Figure 6. Incretin-Based Drugs Report Years Considered
    Figure 7. Global Incretin-Based Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Incretin-Based Drugs Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Incretin-Based Drugs Revenue in 2023
    Figure 10. Incretin-Based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Glucagon-like peptide-1 receptor (GLP-1) agonists Picture
    Figure 12. Dipeptidyl Peptidase-4 (DPP-4) inhibitors Picture
    Figure 13. Global Incretin-Based Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Incretin-Based Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Incretin-Based Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Incretin-Based Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Incretin-Based Drugs Price by Type (2019-2030) & (US$/Unit)
    Figure 18. Product Picture of Oral Drugs
    Figure 19. Product Picture of Injectable Drugs
    Figure 20. Global Incretin-Based Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 21. Global Incretin-Based Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 22. Global Incretin-Based Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 23. Global Incretin-Based Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 24. Global Incretin-Based Drugs Price by Application (2019-2030) & (US$/Unit)
    Figure 25. North America Incretin-Based Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 26. North America Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 27. Europe Incretin-Based Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. Europe Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. Asia Pacific Incretin-Based Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. Asia Pacific Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. South America Incretin-Based Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 32. South America Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 33. Middle East & Africa Incretin-Based Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 34. Middle East & Africa Incretin-Based Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 35. Key Countries/Regions Incretin-Based Drugs Sales Value (%), (2019-2030)
    Figure 36. Key Countries/Regions Incretin-Based Drugs Sales Volume (%), (2019-2030)
    Figure 37. United States Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 38. United States Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 39. United States Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 40. Europe Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Europe Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 42. Europe Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 43. China Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 44. China Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 45. China Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 46. Japan Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Japan Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 48. Japan Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 49. South Korea Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 50. South Korea Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 51. South Korea Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 52. Southeast Asia Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 53. Southeast Asia Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 54. Southeast Asia Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 55. India Incretin-Based Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 56. India Incretin-Based Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 57. India Incretin-Based Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 58. Incretin-Based Drugs Industrial Chain
    Figure 59. Incretin-Based Drugs Manufacturing Cost Structure
    Figure 60. Channels of Distribution (Direct Sales, and Distribution)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS